Short answer
Immunovant, Inc. (IMVT) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$97M
- +23.1% YoY · +36.5% QoQ
- EPS (diluted)
- −$0.47
- +34.7% YoY · +37.3% QoQ
Source: XBRL data from the Immunovant, Inc. (IMVT) Q3 2026 10-Q on SEC EDGAR. USD.
Immunovant, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, reflecting no commercialized products
- Net loss $97.2M vs $126.5M YoY, operating expenses $104.2M vs $131.8M
- Best R&D area, endocrine $22.5M; worst, neurological $18.3M, both down YoY
- Cash $722.3M vs $902.1M at March 31; operating cash used $207.6M
- Cash expected to fund operations through potential GD launch; expanded development could shorten runway
Risk Factors
- No material risk-factor changes during quarter ended September 30, 2026
- Carried-forward risks include potential adverse effects on business, operations, financial condition and cash flows
- Share-price risk: adverse events could reduce Immunovant common-stock value
- Investment risk: shareholders could lose all or part of their investment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Immunovant, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.